LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
LARIMAR THERAPEUTICS, INC. (LRMR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $5.48 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.64, a 0.36% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.62, a 50.62% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.38, a 0.00% change year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $11.38, a 59.31% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $10.08, a 19.49% decline from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $12.52, a 74.88% decline from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $49.85, a 19.34% decline from fiscal 2021.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $61.80.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.48 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $5.64 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | $8.49 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $6.10 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $5.62 10-Q · filed 2025-04-30 | |||
| 2024-12-31 | $10.08 10-K · filed 2025-03-24 | |||
| 2024-09-30 | $10.08 10-Q · filed 2024-10-30 | |||
| 2024-06-30 | $13.39 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $11.38 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $12.52 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $12.79 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $11.53 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $11.38 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $49.85 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $59.60 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $61.54 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $27.97 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $61.80 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |